These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 9316670)

  • 41. Apomorphine: an underutilized therapy for Parkinson's disease.
    Poewe W; Wenning GK
    Mov Disord; 2000 Sep; 15(5):789-94. PubMed ID: 11009181
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Apomorphine: a powerful ally in Parkinson's disease].
    Alonso-Canovas A; Martínez-Castrillo JC
    Rev Neurol; 2021 May; 72(9):323-332. PubMed ID: 33908619
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Literature review: intermittent subcutaneous apomorphine therapy in Parkinson's disease.
    Factor SA
    Neurology; 2004 Mar; 62(6 Suppl 4):S12-7. PubMed ID: 15037666
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Intranasal apomorphine rescue therapy for parkinsonian "off" periods.
    Dewey RB; Maraganore DM; Ahlskog JE; Matsumoto JY
    Clin Neuropharmacol; 1996 Jun; 19(3):193-201. PubMed ID: 8726538
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Other formulations and future considerations for apomorphine for subcutaneous injection therapy.
    Koller W; Stacy M
    Neurology; 2004 Mar; 62(6 Suppl 4):S22-6. PubMed ID: 15037668
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson's disease--Clinical practice recommendations.
    Trenkwalder C; Chaudhuri KR; García Ruiz PJ; LeWitt P; Katzenschlager R; Sixel-Döring F; Henriksen T; Sesar Á; Poewe W; ; Baker M; Ceballos-Baumann A; Deuschl G; Drapier S; Ebersbach G; Evans A; Fernandez H; Isaacson S; van Laar T; Lees A; Lewis S; Martínez Castrillo JC; Martinez-Martin P; Odin P; O'Sullivan J; Tagaris G; Wenzel K
    Parkinsonism Relat Disord; 2015 Sep; 21(9):1023-30. PubMed ID: 26189414
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of the clinical pharmacology of (-)NPA and levodopa in Parkinson's disease.
    Mouradian MM; Heuser IJ; Baronti F; Giuffra M; Conant K; Davis TL; Chase TN
    J Neurol Neurosurg Psychiatry; 1991 May; 54(5):401-5. PubMed ID: 1865201
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Strategies for treating patients with advanced Parkinson's disease with disastrous fluctuations and dyskinesias.
    Stocchi F; Nordera G; Marsden CD
    Clin Neuropharmacol; 1997 Apr; 20(2):95-115. PubMed ID: 9099462
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Apomorphine in treatment of Parkinson's disease with fluctuations].
    Zaleska B; Domzał T
    Neurol Neurochir Pol; 1999; 33(6):1297-303. PubMed ID: 10791032
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Apomorphine in off state--clinical experience].
    Rudzińska M; Szczudlik A
    Neurol Neurochir Pol; 2007; 41(2 Suppl 1):S40-8. PubMed ID: 17941458
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Sublingual administration of apomorphine in the treatment of motor fluctuations in Parkinson disease].
    Durif F; Deffond D; Eschalier A; Tournilhac M
    Rev Neurol (Paris); 1992; 148(10):610-4. PubMed ID: 1295055
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacological Treatment of Tremor in Parkinson's Disease Revisited.
    Pirker W; Katzenschlager R; Hallett M; Poewe W
    J Parkinsons Dis; 2023; 13(2):127-144. PubMed ID: 36847017
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Apomorphine tolerance in Parkinson's disease: lack of a dose effect.
    Gancher ST; Woodward WR; Nutt JG
    Clin Neuropharmacol; 1996 Feb; 19(1):59-64. PubMed ID: 8867518
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Apomorphine therapy in Parkinson's disease: a review.
    Haq IU; Lewitt PA; Fernandez HH
    Expert Opin Pharmacother; 2007 Nov; 8(16):2799-809. PubMed ID: 17956200
    [TBL] [Abstract][Full Text] [Related]  

  • 55. History of levodopa and dopamine agonists in Parkinson's disease treatment.
    Tolosa E; Martí MJ; Valldeoriola F; Molinuevo JL
    Neurology; 1998 Jun; 50(6 Suppl 6):S2-10; discussion S44-8. PubMed ID: 9633679
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Infusional Therapies, Continuous Dopaminergic Stimulation, and Nonmotor Symptoms.
    Mundt-Petersen U; Odin P
    Int Rev Neurobiol; 2017; 134():1019-1044. PubMed ID: 28805563
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Candidate patient for subcutaneous apomorphine injection].
    Chacón JR; Mata M
    Rev Neurol; 2012; 55 Suppl 1():S7-9. PubMed ID: 23169232
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Motor impairment, in patients with severe Parkinson's disease, associated with dopaminergic hyperstimulation (entacapone)].
    Vaamonde J; Ibáñez R; Hernández A; Gudín M; de Luis P; del Real MA
    Neurologia; 2001 Feb; 16(2):81-4. PubMed ID: 11257935
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Subcutaneous continuous apomorphine infusion in fluctuating patients with Parkinson's disease: long-term results.
    Stocchi F; Vacca L; De Pandis MF; Barbato L; Valente M; Ruggieri S
    Neurol Sci; 2001 Feb; 22(1):93-4. PubMed ID: 11487217
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease.
    Colzi A; Turner K; Lees AJ
    J Neurol Neurosurg Psychiatry; 1998 May; 64(5):573-6. PubMed ID: 9598668
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.